# Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

> **NCT04702009** · PHASE2,PHASE3 · COMPLETED · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 33 (actual)

## Conditions studied

- Advanced Lung Carcinoma
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Chemoimmunotherapy (CIT): Sintilimab + Platinum-Based Doublet Chemotherapy
- **PROCEDURE:** Chemoimmunotherapy (CIT): Sintilimab + Platinum-Based Doublet Chemotherapy

## Key facts

- **NCT ID:** NCT04702009
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-20
- **Primary completion:** 2025-10-17
- **Final completion:** 2026-01-20
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04702009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04702009, "Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04702009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*